APTX - Aptinyx musculoskeletal pain drug NYX-2925 fails mid-stage study

• Aptinyx ( NASDAQ: APTX ) said its oral medicine NYX-2925 did not show statistically significant separation from placebo in reducing pain, failing to meet the main goal of a phase 2b trial.
• The study evaluated 2 doses (50mg-100mg) of the drug versus placebo in ~300 patients with fibromyalgia — a disorder that causes widespread musculoskeletal pain.
• The main goal was the change from baseline in average daily pain as reported on the 0-to-10 numeric rating scale (NRS) during week 12 of the study.
• The company said that both doses did not show statistically significant separation from placebo.
• Patients on NYX-2925 at both doses showed a trend toward clinically meaningful improvement in pain, and some secondary goals, versus placebo by week 4. However, by week 12, the placebo group improved such that, although NYX-2925 remained numerically better, the separation was not clinically meaningful, Aptinyx said in an Aug. 12 press release.
• NYX-2925 was well tolerated in the study, and no concerning safety issues were seen, according to the company.
• Aptinyx added that detailed data from the study continue to be evaluated.

For further details see: